---
annotation-target: hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf
---


>%%
>```annotation-json
>{"created":"2022-04-17T01:48:36.818Z","updated":"2022-04-17T01:48:36.818Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":49950,"end":50023},{"type":"TextQuoteSelector","exact":"  lymphoid  progenitor cells in the blood, bone marrow, and other tissues","prefix":"iferation  and  accumulation  of","suffix":". It has a bimodal distribution."}]}]}
>```
>%%
>*%%PREFIX%%iferation  and  accumulation  of%%HIGHLIGHT%% ==lymphoid  progenitor cells in the blood, bone marrow, and other tissues== %%POSTFIX%%. It has a bimodal distribution.*
>%%LINK%%[[#^lo94gmakn78|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^lo94gmakn78


>%%
>```annotation-json
>{"created":"2022-04-17T01:49:55.376Z","updated":"2022-04-17T01:49:55.376Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":50248,"end":50369},{"type":"TextQuoteSelector","exact":".  Approximately  60%  of  cases  are  diagnosed  in  patients ≤20 years old, with a median age at diagnosis of 14 years.","prefix":"around the fifth decade of  life","suffix":" In 2014, the American Cancer So"}]}]}
>```
>%%
>*%%PREFIX%%around the fifth decade of  life%%HIGHLIGHT%% ==.  Approximately  60%  of  cases  are  diagnosed  in  patients ≤20 years old, with a median age at diagnosis of 14 years.== %%POSTFIX%%In 2014, the American Cancer So*
>%%LINK%%[[#^x544xghup|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^x544xghup


>%%
>```annotation-json
>{"created":"2022-04-17T01:50:21.233Z","updated":"2022-04-17T01:50:21.233Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":50500,"end":50653},{"type":"TextQuoteSelector","exact":" Acute lymphoblastic leukemia represents 20% of adult leukemias but is the most common childhood acute leukemia, representing approximately 80% of cases ","prefix":"nosed with ALL that year (1, 2).","suffix":"(1, 2).The etiology of ALL is un"}]}]}
>```
>%%
>*%%PREFIX%%nosed with ALL that year (1, 2).%%HIGHLIGHT%% ==Acute lymphoblastic leukemia represents 20% of adult leukemias but is the most common childhood acute leukemia, representing approximately 80% of cases== %%POSTFIX%%(1, 2).The etiology of ALL is un*
>%%LINK%%[[#^izttkaz0bm|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^izttkaz0bm


>%%
>```annotation-json
>{"created":"2022-04-17T01:51:23.891Z","updated":"2022-04-17T01:51:23.891Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":50712,"end":51339},{"type":"TextQuoteSelector","exact":"Chromosomal  translocations  occurring  in  utero  dur-ing fetal hematopoiesis have suggested genetic factors as  the  primary  cause  for  pediatric  ALL  and  postnatal  genetic  events  as  secondary  contributors.  Monozy-gotic  and  dizygotic  twins  of  patients  with  ALL  and  individuals with genetic disorders, such as Klinefelter (XXY and variants) and Down (trisomy 21) syndromes, or inherited diseases with excessive chromosomal fragility,  such  as  Bloom  syndrome,  Fanconi  anemia,  and ataxia telangiectasia, have all been found to have higher incidence of ALL, implicating a possible genetic predisposition.","prefix":"is unknown in most cases (3-7). ","suffix":" Additional studies have postula"}]}]}
>```
>%%
>*%%PREFIX%%is unknown in most cases (3-7).%%HIGHLIGHT%% ==Chromosomal  translocations  occurring  in  utero  dur-ing fetal hematopoiesis have suggested genetic factors as  the  primary  cause  for  pediatric  ALL  and  postnatal  genetic  events  as  secondary  contributors.  Monozy-gotic  and  dizygotic  twins  of  patients  with  ALL  and  individuals with genetic disorders, such as Klinefelter (XXY and variants) and Down (trisomy 21) syndromes, or inherited diseases with excessive chromosomal fragility,  such  as  Bloom  syndrome,  Fanconi  anemia,  and ataxia telangiectasia, have all been found to have higher incidence of ALL, implicating a possible genetic predisposition.== %%POSTFIX%%Additional studies have postula*
>%%LINK%%[[#^odqsdhy5r9c|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^odqsdhy5r9c


>%%
>```annotation-json
>{"created":"2022-04-17T01:51:43.506Z","updated":"2022-04-17T01:51:43.506Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":51744,"end":51787},{"type":"TextQuoteSelector","exact":"varicella has been linked to childhood ALL ","prefix":" and mature B-cell ALL (6); and ","suffix":"(7).CLINICAL PRESENTATION AND LA"}]}]}
>```
>%%
>*%%PREFIX%%and mature B-cell ALL (6); and%%HIGHLIGHT%% ==varicella has been linked to childhood ALL== %%POSTFIX%%(7).CLINICAL PRESENTATION AND LA*
>%%LINK%%[[#^wjuea0qw1g|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^wjuea0qw1g


>%%
>```annotation-json
>{"created":"2022-04-17T01:52:51.292Z","updated":"2022-04-17T01:52:51.292Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":51914,"end":52353},{"type":"TextQuoteSelector","exact":" They  largely  reflect  bone  marrow  failure  and include malaise, fatigue, bleeding or bruising, and secondary infections. The B symptoms, such as fever, night  sweats,  and  weight  loss,  are  frequent.  White  blood cell (WBC) count at presentation varies widely, and  circulating  blasts  are  generally  noted.  Symptoms  related to hyperleukocytosis are rare in ALL, given the lymphoblast morphology, even when WBC counts are high","prefix":"c,  particularly  in  children. ","suffix":".Leukemic involvement of the cen"}]}]}
>```
>%%
>*%%PREFIX%%c,  particularly  in  children.%%HIGHLIGHT%% ==They  largely  reflect  bone  marrow  failure  and include malaise, fatigue, bleeding or bruising, and secondary infections. The B symptoms, such as fever, night  sweats,  and  weight  loss,  are  frequent.  White  blood cell (WBC) count at presentation varies widely, and  circulating  blasts  are  generally  noted.  Symptoms  related to hyperleukocytosis are rare in ALL, given the lymphoblast morphology, even when WBC counts are high== %%POSTFIX%%.Leukemic involvement of the cen*
>%%LINK%%[[#^x2owe69lkg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^x2owe69lkg


>%%
>```annotation-json
>{"created":"2022-04-17T01:53:04.775Z","updated":"2022-04-17T01:53:04.775Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":52354,"end":52411},{"type":"TextQuoteSelector","exact":"Leukemic involvement of the central nervous system (CNS) ","prefix":", even when WBC counts are high.","suffix":"ranging from cranial neuropathie"}]}]}
>```
>%%
>*%%PREFIX%%, even when WBC counts are high.%%HIGHLIGHT%% ==Leukemic involvement of the central nervous system (CNS)== %%POSTFIX%%ranging from cranial neuropathie*
>%%LINK%%[[#^q1pnmfeaa7|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^q1pnmfeaa7


>%%
>```annotation-json
>{"created":"2022-04-17T01:53:10.606Z","updated":"2022-04-17T01:53:10.606Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":52544,"end":52581},{"type":"TextQuoteSelector","exact":"mature B-cell ALL (Burkitt  leukemia)","prefix":"enta-tion. It is more common in ","suffix":" (8). A history or findings of a"}]}]}
>```
>%%
>*%%PREFIX%%enta-tion. It is more common in%%HIGHLIGHT%% ==mature B-cell ALL (Burkitt  leukemia)== %%POSTFIX%%(8). A history or findings of a*
>%%LINK%%[[#^ys52thvbipg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ys52thvbipg


>%%
>```annotation-json
>{"created":"2022-04-17T01:57:21.940Z","updated":"2022-04-17T01:57:21.940Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":52587,"end":52926},{"type":"TextQuoteSelector","exact":"A history or findings of abdominal masses, significant spontaneous tumor lysis syndrome, and  chin  numbness  (mental  nerve)  indicating  cranial  nerve involvement are also more common in this sub-type of ALL (9). Lymphadenopathy and hepatospleno-megaly,  although  rarely  symptomatic,  are  noted  in  approximately 20% of patients (9)","prefix":"ll ALL (Burkitt  leukemia) (8). ","suffix":".4 Section I LeukemiaCHAPTER 1DI"}]}]}
>```
>%%
>*%%PREFIX%%ll ALL (Burkitt  leukemia) (8).%%HIGHLIGHT%% ==A history or findings of abdominal masses, significant spontaneous tumor lysis syndrome, and  chin  numbness  (mental  nerve)  indicating  cranial  nerve involvement are also more common in this sub-type of ALL (9). Lymphadenopathy and hepatospleno-megaly,  although  rarely  symptomatic,  are  noted  in  approximately 20% of patients (9)== %%POSTFIX%%.4 Section I LeukemiaCHAPTER 1DI*
>%%LINK%%[[#^1zg1hfrsk3j|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^1zg1hfrsk3j


>%%
>```annotation-json
>{"created":"2022-04-17T01:59:11.308Z","updated":"2022-04-17T01:59:11.308Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":56422,"end":56492},{"type":"TextQuoteSelector","exact":"Diagnosis of acute lymphoblastic leukemia. AML, acute myeloid leukemia","prefix":"lecular abnormalitiesFIGURE 1-1 ","suffix":". Chapter 1 Acute Lymphoblastic "}]}]}
>```
>%%
>*%%PREFIX%%lecular abnormalitiesFIGURE 1-1%%HIGHLIGHT%% ==Diagnosis of acute lymphoblastic leukemia. AML, acute myeloid leukemia== %%POSTFIX%%. Chapter 1 Acute Lymphoblastic*
>%%LINK%%[[#^iu382vyu32c|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^iu382vyu32c


>%%
>```annotation-json
>{"created":"2022-04-17T02:32:11.611Z","updated":"2022-04-17T02:32:11.611Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":58432,"end":58470},{"type":"TextQuoteSelector","exact":"Immunophenotypic Classification of ALL","prefix":"verall incidence <10%.Table 1-1 ","suffix":"B Lineage T LineageCD19/CD79a/CD"}]}]}
>```
>%%
>*%%PREFIX%%verall incidence <10%.Table 1-1%%HIGHLIGHT%% ==Immunophenotypic Classification of ALL== %%POSTFIX%%B Lineage T LineageCD19/CD79a/CD*
>%%LINK%%[[#^6quragc7fd2|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^6quragc7fd2


>%%
>```annotation-json
>{"created":"2022-04-17T02:39:35.161Z","updated":"2022-04-17T02:39:35.161Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":60619,"end":60816},{"type":"TextQuoteSelector","exact":"Observations  of  epigenetic  alterations  regulating  distinct molecular pathways that occur frequently at  presentation  and  relapse  have  identified  a  “hyper-methylator”  phenotype  of  ALL ","prefix":"s  subgroup  with  poor outcome.","suffix":" (27).  These  patients  may res"}]}]}
>```
>%%
>*%%PREFIX%%s  subgroup  with  poor outcome.%%HIGHLIGHT%% ==Observations  of  epigenetic  alterations  regulating  distinct molecular pathways that occur frequently at  presentation  and  relapse  have  identified  a  “hyper-methylator”  phenotype  of  ALL== %%POSTFIX%%(27).  These  patients  may res*
>%%LINK%%[[#^j2x090qzjw|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^j2x090qzjw


>%%
>```annotation-json
>{"created":"2022-04-17T03:07:54.615Z","updated":"2022-04-17T03:07:54.615Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":61153,"end":61334},{"type":"TextQuoteSelector","exact":"Therapy  for  ALL  consists  of  complex  and  compre-hensive  regimens  consisting  of  several  phases:  induc-tion, intensified consolidation, maintenance, and CNS  prophylaxis (","prefix":"able 1-3) (28).FRONTLINE THERAPY","suffix":"9,29). Each involves the use of "}]}]}
>```
>%%
>*%%PREFIX%%able 1-3) (28).FRONTLINE THERAPY%%HIGHLIGHT%% ==Therapy  for  ALL  consists  of  complex  and  compre-hensive  regimens  consisting  of  several  phases:  induc-tion, intensified consolidation, maintenance, and CNS  prophylaxis (== %%POSTFIX%%9,29). Each involves the use of*
>%%LINK%%[[#^xgwgzza4f3c|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^xgwgzza4f3c


>%%
>```annotation-json
>{"created":"2022-04-17T09:10:18.713Z","text":"联合蒽环类药物（如道诺-鲁比星或阿霉素）、长春新碱和地塞米沙酮（为了更好的中枢神经系统渗透），通常与环磷酰胺或天冬酰胺酶联合生长因子支持，是ALL诱导方案的基石。","updated":"2022-04-17T09:10:18.713Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":61732,"end":62001},{"type":"TextQuoteSelector","exact":"Combining anthracyclines (eg, dauno-rubicin  or  doxorubicin),  vincristine,  and  dexametha-sone (for better CNS penetration), often coupled with cyclophosphamide or asparaginase with growth factor support,  represents  the  cornerstone  of  ALL  induction  regimens. ","prefix":" and maintenance phases (9,30). ","suffix":"This results in complete remissi"}]}]}
>```
>%%
>*%%PREFIX%%and maintenance phases (9,30).%%HIGHLIGHT%% ==Combining anthracyclines (eg, dauno-rubicin  or  doxorubicin),  vincristine,  and  dexametha-sone (for better CNS penetration), often coupled with cyclophosphamide or asparaginase with growth factor support,  represents  the  cornerstone  of  ALL  induction  regimens.== %%POSTFIX%%This results in complete remissi*
>%%LINK%%[[#^hkknipqhmos|show annotation]]
>%%COMMENT%%
>联合蒽环类药物（如道诺-鲁比星或阿霉素）、长春新碱和地塞米沙酮（为了更好的中枢神经系统渗透），通常与环磷酰胺或天冬酰胺酶联合生长因子支持，是ALL诱导方案的基石。
>%%TAGS%%
>
^hkknipqhmos


>%%
>```annotation-json
>{"created":"2022-04-17T09:14:41.584Z","text":"阿糖胞苷、甲基三羟甲酸盐、环磷酰胺和6-巯基嘌呤","updated":"2022-04-17T09:14:41.584Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":62315,"end":62382},{"type":"TextQuoteSelector","exact":"cytarabine,  metho-trexate, cyclophosphamide, and 6-mercaptopurine)","prefix":"  consolidation  chemotherapy  (","suffix":" or  allogeneic  hematopoietic  "}]}]}
>```
>%%
>*%%PREFIX%%consolidation  chemotherapy  (%%HIGHLIGHT%% ==cytarabine,  metho-trexate, cyclophosphamide, and 6-mercaptopurine)== %%POSTFIX%%or  allogeneic  hematopoietic*
>%%LINK%%[[#^gvuwi6ju3ql|show annotation]]
>%%COMMENT%%
>阿糖胞苷、甲基三羟甲酸盐、环磷酰胺和6-巯基嘌呤
>%%TAGS%%
>
^gvuwi6ju3ql


>%%
>```annotation-json
>{"created":"2022-04-17T09:17:01.894Z","text":"虽然大剂量阿糖胞苷（1-7.5 mg/m2）和甲氨蝶呤（5-8 g/m2）成功穿透血脑屏障，但它们毒性太大，不能作为唯一的中枢神经系统预防药物。纳入 IT 预防（甲氨蝶呤、胱氨酸盐、脂质体阿糖胞苷、氢化可的松或噻替哌）通过允许脑脊液中药物的持续治疗浓度，将中枢神经系统复发的发生率降低至 4%","updated":"2022-04-17T09:17:01.894Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":63020,"end":63441},{"type":"TextQuoteSelector","exact":" Although high-dose cytarabine (1-7.5 mg/m2) and methotrexate  (5-8 g/m2) successfully penetrate the blood-brain barrier, they are too toxic to serve as the sole CNS prophylaxis. The inclusion of IT prophylaxis (methotrexate, cytara-bine, liposomal cytarabine, hydrocortisone, or thiotepa) reduces the incidence of CNS relapse to 4% by allowing sustained therapeutic concentration of the agents in the cerebrospinal fluid","prefix":"rathecal chemotherapy (IT) (31).","suffix":". The number of ITs varies accor"}]}]}
>```
>%%
>*%%PREFIX%%rathecal chemotherapy (IT) (31).%%HIGHLIGHT%% ==Although high-dose cytarabine (1-7.5 mg/m2) and methotrexate  (5-8 g/m2) successfully penetrate the blood-brain barrier, they are too toxic to serve as the sole CNS prophylaxis. The inclusion of IT prophylaxis (methotrexate, cytara-bine, liposomal cytarabine, hydrocortisone, or thiotepa) reduces the incidence of CNS relapse to 4% by allowing sustained therapeutic concentration of the agents in the cerebrospinal fluid== %%POSTFIX%%. The number of ITs varies accor*
>%%LINK%%[[#^sq0fqruyed8|show annotation]]
>%%COMMENT%%
>虽然大剂量阿糖胞苷（1-7.5 mg/m2）和甲氨蝶呤（5-8 g/m2）成功穿透血脑屏障，但它们毒性太大，不能作为唯一的中枢神经系统预防药物。纳入 IT 预防（甲氨蝶呤、胱氨酸盐、脂质体阿糖胞苷、氢化可的松或噻替哌）通过允许脑脊液中药物的持续治疗浓度，将中枢神经系统复发的发生率降低至 4%
>%%TAGS%%
>
^sq0fqruyed8


>%%
>```annotation-json
>{"created":"2022-04-17T09:18:31.144Z","updated":"2022-04-17T09:18:31.144Z","document":{"title":"The MD Anderson Manual of Medical Oncology, Third Edition","link":[{"href":"urn:x-pdf:fbf5eba54413eb47949df750f6190ec9"},{"href":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf"}],"documentFingerprint":"fbf5eba54413eb47949df750f6190ec9"},"uri":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","target":[{"source":"vault:/hematology-theroy/books/The MD Anderson Manual of Medical Oncology by Hagop M. Kantarjian, Robert A. Wolff (z-lib.org).pdf","selector":[{"type":"TextPositionSelector","start":63846,"end":63915},{"type":"TextQuoteSelector","exact":"(usually 8 for standard risk, 12 for Ph posi-tive, and 16 for Burkitt","prefix":" Leukemia 7CHAPTER 1to protocol ","suffix":"), and in rare cases of extramed"}]}]}
>```
>%%
>*%%PREFIX%%Leukemia 7CHAPTER 1to protocol%%HIGHLIGHT%% ==(usually 8 for standard risk, 12 for Ph posi-tive, and 16 for Burkitt== %%POSTFIX%%), and in rare cases of extramed*
>%%LINK%%[[#^fyrtpadhree|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^fyrtpadhree
